Birgit Kjældgaard Giwercman
Director Ejecutivo en BKG Pharma ApS .
Perfil
Birgit Kjældgaard Giwercman is the founder and the Chief Executive Officer of BKG Pharma ApS, which was founded in 2004.
She is also currently the Chief Executive Officer of BKG Vet Pharma ApS since 2011.
In addition to her founding and current positions, Dr. Giwercman has held former positions as a Director at Pantheco A and Cureon A.
She also served as an Associated Professor at the University of Copenhagen.
Dr. Giwercman obtained her doctorate degree from the University of Copenhagen in 1983.
Cargos activos de Birgit Kjældgaard Giwercman
| Empresas | Cargo | Inicio |
|---|---|---|
BKG Pharma ApS
 BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Director Ejecutivo | 15/03/2010 |
| BKG Vet Pharma ApS | Director Ejecutivo | 01/01/2011 |
Antiguos cargos conocidos de Birgit Kjældgaard Giwercman.
| Empresas | Cargo | Fin |
|---|---|---|
Pantheco A/S
 Pantheco A/S Pharmaceuticals: MajorHealth Technology Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics. | Director/Miembro de la Junta | - |
Cureon A/S
 Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Director/Miembro de la Junta | - |
| University of Copenhagen | Corporate Officer/Principal | - |
Formación de Birgit Kjældgaard Giwercman.
| University of Copenhagen | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
BKG Pharma ApS
BKG Pharma ApS Pharmaceuticals: MajorHealth Technology BKG Pharma ApS develops and commercializes novel antibiotics against multidrug-resistant bacteria. It conducts research and development on treatment for multi-resistant infections such as resistance to chemotherapy. The company was founded by Birgit K. Giwercman in 2004 and is headquartered in Copenhagen, Denmark. | Health Technology |
Pantheco A/S
Pantheco A/S Pharmaceuticals: MajorHealth Technology Pantheco A/S is a Danish biotech company, whose mission it is to develop drugs based upon Peptide Nucleic Acid (PNA) for the treatment of infectious diseases caused by resistant microorganisms. Pantheco represents a spin-off of the research activities and know-how within the Peptide Nucleic Acid (PNA) antisense technology invented at University of Copenhagen in 1992 and the PNA Patent Rights licensed from Isis Pharmaceuticals, Inc. in US. By employing the PNA technology, chemistry, know-how, and the exclusive rights for human therapeutic uses within anti-infectives, Pantheco has the unique opportunity to generate novel classes of anti-infective drugs and become a world class leader within novel generations of antisense therapeutics. | Health Technology |
Cureon A/S
Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Health Technology |
| BKG Vet Pharma ApS |
- Bolsa de valores
- Insiders
- Birgit Kjældgaard Giwercman
